Best Gene Editing CDMOs in United States
· updated as new inspection, certificate, and trial data enters the platform
9
CDMOs tracked
9
Fully scored
4
With FDA records
18
FDA inspections
31
EMA/MHRA GMP certs
Gene editing CDMOs support CRISPR, base, and prime editing programs — spanning guide RNA and nuclease (mRNA or protein) supply, delivery (LNP, AAV, or electroporation), and, for ex vivo programs, edited-cell manufacturing.
Because a gene-editing program touches several modalities at once, CDMO selection often hinges on which steps a partner covers in-house versus coordinates. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 11 NAI (no action), 6 VAI (voluntary action), 1 OAI (official action). Leading inspection & GMP sites: Germany (17), United States (15), France (4), Ireland (3), UNITED KINGDOM (3).
Last updated 2026-07-11. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
BY
Bayer (Cell Therapy Mfg)
Berkeley, CA
|
80.4 | 90.1 | 8 insp · 18 GMP | — | 126 programs |
| 2 |
CS
Cedars-Sinai Biomanufacturing
Los Angeles, CA
|
79.8 | 100.0 | 1 insp · 0 GMP | — | 34 programs |
| 3 |
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
90.9 | 98.3 | 8 insp · 11 GMP | Limited | 0 programs |
| 4 |
RC
RoslinCT
Edinburgh, UK · Hopkinton, MA
|
80.3 | 99.0 | 1 insp · 1 GMP | Available | 0 programs |
| 5 |
GP
Green Phoenix Labs
San Diego, CA
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 6 |
CT
CTMC
Houston, TX
|
63.0 | — | — | — | 0 programs |
| 7 |
C3
C3i Center
Houston, TX
|
59.0 | — | — | — | 0 programs |
| 8 |
AP
Applied StemCell
Milpitas, CA
|
59.0 | — | — | — | 0 programs |
| 9 |
PO
Poseida Therapeutics (CDMO)
San Diego, CA
|
58.7 | — | — | — | 6 programs |
What to evaluate in a Gene Editing CDMO
Editing components
Confirm supply of guide RNA and nuclease (Cas mRNA or protein) — in-house or sourced — and the quality controls on each.
Delivery modality
In vivo editing needs LNP or AAV delivery; ex vivo needs electroporation and cell handling. Match the CDMO's delivery experience to your approach.
Ex vivo cell manufacturing
For edited cell therapies, evaluate closed-system cell processing and chain-of-identity, as with other cell therapies.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
FDA jurisdiction — how the ranking scores US-based CDMOs
The Signal Score's Quality Compliance pillar (35% of the composite) is dominated by FDA inspection data for US-based CDMOs: Establishment Inspection Report classifications (NAI, VAI, OAI), Form 483 observation counts, and Warning Letter history. For a CDMO whose primary facility footprint is US, this pillar carries direct weight — an inspection on the site slated for a sponsor's program applies without translation. For CDMOs with mixed US + international facility footprint, the ranking reflects the composite regulatory posture; sponsors evaluating for a specific program should verify inspection history on the exact US site under consideration via that CDMO's profile page.
Which US CDMOs also cover EU and UK regulatory geographies?
Many top-tier US-based CDMOs maintain EU (EMA) and UK (MHRA) GMP certification for facilities used to supply EU and UK trials or commercial markets. The Signal Score's Quality Compliance pillar includes EMA + MHRA certificate density as a component — a US-headquartered CDMO with dense EU/UK certificates typically ranks higher on this pillar than a US-only competitor. Sponsors running dual-jurisdiction programs should cross-check the individual CDMO profile pages for specific certificate coverage; the Europe region ranking surfaces CDMOs that also appear in the European jurisdiction ranking, indicating multi-region regulatory posture.
How CDMO Signal identifies US manufacturing presence
Region attribution is derived from each CDMO's declared facility locations in our directory. A CDMO's facility list is validated against corporate filings, press releases, and — where public — the FDA facility registration (FEI number lookups). Region matching is done at the country level: a US state name or two-letter abbreviation in the facility list places the CDMO in the US region. CDMOs with US + international sites appear in every applicable region ranking, which reflects operational reality — such a CDMO is a legitimate candidate for programs in any of those jurisdictions.
Gene Editing CDMOs — Frequently Asked Questions
Who are the top Gene Editing CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Gene Editing CDMOs include Bayer (Cell Therapy Mfg), Cedars-Sinai Biomanufacturing, Charles River Laboratories. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Gene Editing CDMOs have FDA inspection records?
CDMO Signal tracks 4 Gene Editing CDMOs with FDA inspection records and 31 EMA/MHRA GMP certificates across the group.
What should I look for in a gene editing CDMO?
Map the steps you need — guide RNA and nuclease supply, delivery (LNP/AAV/electroporation), and edited-cell manufacturing — and confirm which the CDMO covers in-house versus coordinates, plus a clean FDA and EMA/MHRA record.
Why do gene editing programs use multiple CDMOs?
A single program may need guide RNA, a nuclease, a delivery vehicle, and cell manufacturing — distinct capabilities. Some CDMOs cover several in-house; many programs combine specialists.
Related modalities